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Undifferentiated thyroid carcinoma is one of the most aggressive human cancers with frequent RAS mutations.
Howmutations of theRAS gene contribute to undifferentiated thyroid cancer remains largely unknown.Mice harboring
a potent dominant negative mutant thyroid hormone receptor β, TRβPV (ThrbPV/PV), spontaneously develop well-
differentiated follicular thyroid cancer similar to human cancer.Wegenetically targeted theKrasG12Dmutation to thyroid
epithelial cells of ThrbPV/PV mice to understand how KrasG12D mutation could induce undifferentiated thyroid cancer in
ThrbPV/PVKrasG12D mice. ThrbPV/PVKrasG12D mice exhibited poorer survival due to more aggressive thyroid tumors with
capsular invasion, vascular invasion, and distant metastases to the lung occurring at an earlier age and at a higher
frequency than ThrbPV/PV mice did. Importantly, ThrbPV/PVKrasG12D mice developed frequent anaplastic foci with
complete loss of normal thyroid follicular morphology. Within the anaplastic foci, the thyroid-specific transcription
factor paired box gene 8 (PAX8) expression was virtually lost and the loss of PAX8 expression was inversely correlated
with elevated MYC expression. Consistently, co-expression of KRASG12D with TRβPV upregulated MYC levels in rat
thyroid pccl3 cells, andMYCacted to enhance the TRβPV-mediated repression of thePax8promoter activity of a distant
upstream enhancer, critical for thyroid-specific Pax8 expression. Our findings indicated that synergistic signaling of
KRASG12D and TRβPV led to increased MYC expression. Upregulated MYC contributes to the initiation
of undifferentiated thyroid cancer, in part, through enhancing TRβPV-mediated repression of the Pax8 expression.
Thus, MYC might serve as a potential target for therapeutic intervention.
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Thyroid cancer is themost commonmalignancy of the endocrine organs.
The follicular cell–derived cancers are classified into well-differentiated
papillary and follicular carcinomas, poorly differentiated carcinoma, and
undifferentiated carcinoma. Undifferentiated thyroid carcinoma is one of
the most aggressive malignancies. It spreads quickly to other organs and
does not respond well to radioiodine therapy. So far, no effective target
treatments are available. Ten-year survival rate is less than 10% [1].
Among prevalent genetic alterations found in undifferentiated thyroid
cancer are point mutations of the RAS, TP53, and CTNNB1 genes.
Pathway analysis shows that these mutations lead to activated mitogen-
activated protein kinases (MAPK) and phosphatidylinositol 3-kinase
(PI3K)–protein kinase B (AKT) signaling pathways critical for the
development of thyroid cancer. While mutations in the TP53 and
CTNNB1 genes are found only in undifferentiated thyroid cancers [1],
mutations in the RAS gene are frequently found in well-differentiated
thyroid cancer. These RAS mutations could represent an early event in
thyroid carcinogenesis. It is unclear, however, how RAS mutations couldinitiate undifferentiated thyroid carcinoma, especially in view of the
findings that theRasmutations alone in the thyroid failed to induce thyroid
cancer in mice [2,3].
Previously, we demonstrated that mice with a mutant thyroid
hormone receptor β, TRβPV (ThrbPV/PV), spontaneously develop
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progression and frequency of metastasis as in human thyroid
cancer [4,5]. The PV mutation was originally identified in a
patient with resistance to thyroid hormone [6]. The PV mutation
has completely lost T3 binding activity and transcription capacity.
It acts to abnormally regulate the expression of the T3 target gene
through dominant negative activity. Detailed pathway analysis in
the thyroid tumors of ThrbPV/PV mice indicated that the PI3K-
AKT signaling pathway, which is frequently activated in
undifferentiated thyroid carcinoma [7], is aberrantly overactivated
in ThrbPV/PV mice [8]. CTNNB1 signaling is also increased in
these mice [9,10], which was proposed to initiate tumor
dedifferentiation in the late stage of tumorigenesis [1]. However,
the RAS mutant–activated MAPK pathway, critical for undiffer-
entiated thyroid carcinoma, is apparently not altered in the
thyroid of ThrbPV/PV mice. We hypothesized that activation of the
MAPK pathway driven by RAS mutation in the thyroid of
ThrbPV/PV mice might phenotypically mimic the altered signaling
observed in human thyroid cancer, thereby initiating undifferen-
tiated thyroid cancer.
To investigate this question, we genetically introduced the
KrasG12D mutation to express specifically in the thyroids of the
ThrbPV/PV mice. Our aim was to learn whether the mice with
ThrbPV and KrasG12D double mutations would begin developing
undifferentiated thyroid carcinoma. Indeed, we found the
occurrence of anaplastic foci with a high frequency in the thyroid
of ThrbPV/PVKrasG12D mice. These anaplastic foci had lost normal
thyroid follicular morphology and the expression of transcription
factor paired box gene 8 (PAX8). We demonstrated that synergistic
signaling of TRβPV and KRASG12D mutants led to an elevated
level of MYC protein to suppress the Pax8 expression through a
Pax8 upstream enhancer. Thus, our study established a mouse
model of undifferentiated thyroid cancer that could further be
used to understand altered signaling pathways of undifferentiated
thyroid cancer.
Materials and Methods
Experimental Animals
All animal experiments were performed according to the protocols
approved by the Animal Care and Use Committee at the National
Cancer Institute. The ThrbPV/+, KrasLSL-G12D/+, TPO-Cre (Cre) mice
were previously described [4,11,12]. Mice were in a mixed C57BL/6
and 129Svj genetic background. Thyroids and other tissues were
harvested from the mice and wild-type (WT) littermates for weighing,
histologic analysis, and biochemical studies.
Generation of Rat pccl3 Cell Lines Stably Expressing TRβ,
TRβPV, or MYC
Rat thyroid pccl3 cells were cultured in Ham's F-12 medium
supplemented with 10% FBS and containing six hormones (1 mU/ml
bovine thyroid stimulating hormone (TSH), 10 μg/ml insulin, 5 μg/
ml transferrin, 10 ng/ml glycyl-L-histidyl-L-lysine, 10 ng/ml
somatostatin, and 0.36 ng/ml hydrocortisone; 6H medium). The
pccl3 cells were transfected with an expression plasmid containing
cDNA encoding THRB, THRBPV, MYC, or the control empty
vectors and selected with G418, puromycin (Invitrogen, Carlsbad,
CA), or blasticidin for 2 weeks. The expression of TRβ, TRβPV, or
MYC protein was verified by Western blot analysis using monoclonal
anti-TRβ/anti-TRβPV antibody (J53) or anti-MYC antibody.Adenovirus Infection of Rat pccl3 Cells Expressing TRβ,
TRβPV, or KRASG12D
Rat thyroid pccl3 cells were cultured in Ham's F-12 medium
supplemented with 10% FBS and containing six hormones. Before
addition of adenovirus, the cells were cultured inOpti-MEM Imedium
(Life Science, Grand Island, NY). The pccl3 cells were infected with
adenovirus at a 5:1 ratio of adenovirus to pccl3 cells. After 5 hours, the
mediumwas changed toHam's F-12medium supplemented with 10%
thyroid hormone deficient serum (Td) and containing six hormones in
the absence or presence of 100 nM T3. After 18 hours, the cells were
collected for the preparation of total RNA or to prepare cell lysates for
Western blot analysis.
Western Blot Analysis
The Western blot analysis was carried out as described by
Furumoto et al. [13]. Primary antibodies for phosphorylated
extracellular signal regulated kinase (ERK) (p-ERK; #4376S), total
ERK (#9102), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; #2118) were purchased from Cell Signaling Technology
(Danvers, MA). anti-TTF1 (sc-13040) antibody was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). anti-PAX8 antibody
(10336-1-AP) was purchased from Proteintech Group, Inc. (Chicago,
IL). Cyclin D1 (RB-9041-P0) was purchased from Neomarkers
(Fremont, CA). Antibodies were used at a concentration recommended
by the manufacturers. For control of protein loading, the blot was
probed with the antibody against GAPDH.
Electrophoretic Mobility Gel Shift Assays
Electrophoretic mobility gel shift assay was conducted similarly as
described in [14]. Briefly, the [α-32P]-dCTP–labeled probes were
incubated with the in vitro synthesized TRβ1, TRβ1PV, RXRβ, or
MYC and the reaction mixture was analyzed by 5% polyacrylamide
gel electrophoresis. The gel was dried and autoradiographed.
Histologic Analysis and Immunohistochemistry
Thyroid glands, heart, and lung were dissected and embedded in
paraffin. Five-micrometer-thick sections were prepared and stainedwith
hematoxylin and eosin (H&E). For eachmouse, single random sections
through the thyroid, lung, and heart were examined. Immunohisto-
chemistry was performed with paraffin sections by standard methods.
Dewaxed sections were treated with 0.05% citraconic anhydride buffer
(pH 7.4) at 98°C for 45 minutes to expose the antigen epitopes. A
primary antibody against TTF1 (sc-13040, Santa Cruz Biotechnology),
PAX8 (10336-1-AP; Proteintech), or β-catenin (#9562 s; Cell Signaling
Technology) was incubated with tissue section overnight at 4°C.
Peroxidase activity from the secondary antibody was detected by adding
substrate 3,3′-diaminobenzidine, and the sections were counterstained
with hematoxylin. Bromodeoxyuridine (BrdU) incorporation assay was
performed similarly as described in Zhao et al. [15].
Hormone Assays
The serum levels of total T4 (TT4) and T3 (TT3) were determined
by using a Gamma Coat T4 and T3 assay RIA kit. TSH levels in
serum were measured as described [15].
RNA Extraction and Real-Time Reverse
Transcription–Polymerase Chain Reaction
Total RNA from thyroids was isolated using TRIzol (Invitrogen),
as indicated by the protocol of the manufacturer. Real-time reverse
transcription–polymerase chain reaction (RT-PCR) was performed
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CA), following the instructions of the manufacturer. Primers were as
follows: for mouse Pax8, forward, 5′-cacccttcaatgcctttcc-3′; reverse,
5′-aatacggggtgtggctgtag-3′; for the endogenous control gene mouse
Gapdh, forward, 5′-cgtcccgtagacaaaatggt-3′; reverse, 5′-gaatttgccgt
gagtggagt-3′.
Luciferase Reporter Assay
The Pax8 upstream enhancer element cloned into pGL3b
(CNS87-pGL3b) was generously provided by Dr R. Di Lauro [16].
Established rat thyroid pccl3 cells stably expressing TRβ, TRβPV, or
MYC were seeded at a density of 5 × 105 in six-well culture plates and
preincubated for 24 hours with Td medium. Cells were transfected
using Lipofectamine 2000 (Invitrogen). Cells were lysed 24 hours
later with 1× cell lysis buffer (Promega, Madison, WI), and luciferase
activity was measured using Victor 3 (PerkinElmer Life and Analytical
Sciences, Waltham, MA). Luciferase values were standardized to the
ratio of β-galactosidase activity and protein concentration.
Statistical Analysis
All data are expressed as means ± standard errors. Statistical analysis
was performed and P b .05 was considered significant. All statistical
tests were two-sided. GraphPad Prism version 5.0 for Mac OS X was
used to perform Kaplan-Meier cumulative survival analysis, Student's
t test, Chi-square test, and analysis of variances (ANOVAs).
Results
ThrbPV/PVKrasG12D Mice Manifest Poor Survival with
Markedly Enlarged Thyroids
To investigate whether ThrbPV/PVKrasG12D mice develop undifferen-
tiated thyroid cancer, we targeted the KrasG12D mutation to the thyroid
epithelial cells ofThrbPV/PV mice throughTPO-Cre–mediated expression
of the KrasG12D gene after removal of the STOP cassette. We crossed
three lines of ThrbPV/+, KrasLSL-G12D/+, and TPO-Cre mice to generate
the mice with four different genotypes: Thrb+/+Kras+/+Cre−,
Thrb+/+KrasLSL-G12D/+Cre+, ThrbPV/PVKras+/+Cre−, and ThrbPV/PV
KrasLSL-G12D/+Cre+, and we designate them in the following description
as WT, KrasG12D, ThrbPV/PV, and ThrbPV/PVKrasG12D mice, respectively.
To examine whether the expression of the KrasG12D and the Cre
genes in the thyroids of ThrbPV/PVKrasG12D mice led to functional
activation of the MAPK signaling, we evaluated the phosphorylation
status of the downstream effector, ERK. p-ERK, a signature of
downstream Ras signaling, was assessed by Western blot analysis
(Figure 1A, I-a). GAPDH was used as the loading control (Figure 1A,
I-e). The protein levels of p-ERK were increased by ~5- and 14-fold
in KrasG12D and ThrbPV/PVKrasG12D mice, respectively (compare
lanes 3 and 4 with 1 and 2, and lanes 7 and 8 with 5 and 6; Figure 1A,
I-a), indicating that the KrasG12D mutant was functionally expressed
in the thyroids of ThrbPV/PVKrasG12D mice. There was also a higher
p-ERK activation in ThrbPV/PVKrasG12D mice than in KrasG12D mice
(compare lanes 7 and 8 with lanes 3 and 4). In addition, we also found
that AKT was more activated in thyroid tumors of ThrbPV/PVKrasG12D
mice (lanes 7 and 8) than in ThrbPV/PV mice (lanes 5 and 6) and
KrasG12D mice (lanes 3 and 4; Figure 1A, I-c and I-d). Quantitative
analysis of p-ERK, total ERK, p-AKT, and total AKT band intensities
indicated that the p-ERK/total ERK ratio and p-AKT/total AKT was
1.5-fold and 1.9-fold higher in ThrbPV/PVKrasG12D mice than in
KrasG12D mice, respectively (Figure 1A, II and III). Previously, we have
shown that AKTwas activated in thyroid tumors ofThrbPV/PVmice [8].These results suggest the contribution of TRβPV in the further
activating of KRASG12D and AKT signaling.
Analysis of Kaplan-Meier cumulative survival curves was conducted
for WT, KrasG12D, ThrbPV/PV, and ThrbPV/PVKrasG12D mice over a
period of 10.5 months (Figure 1B). No WT mice or KrasG12D mice
died during that period, but about 30% of ThrbPV/PV mice died. By
contrast, only 50% of ThrbPV/PVKrasG12D mice lived to the age of 4.8
months, and none survived beyond 10.5 months. The differences
between the survival rates of the ThrbPV/PV and ThrbPV/PVKrasG12D
mice were highly significant (P b .01). These results indicate that
synergistic effects of TRβPV and KRASG12D mutants led to poor
survival of ThrbPV/PVKrasG12D mice.
The thyroid weights of KrasG12D mice (3.6 ± 0.6 mg, n = 13) were
similar to those of WT mice (2.7 ± 0.3 mg, n = 13; Figure 1C, bar 2
vs 1). This observation is consistent with a previous report that
KrasG12D mutation alone is not sufficient to increase the thyroid
weight [2]. The thyroid of ThrbPV/PV mice was markedly enlarged
with an average weight of 84 mg (84.47 ± 11.11 mg, n = 29). Among
mice with four genotypes, the double mutant mice had the largest
thyroid (216.7 ± 18.52 mg, n = 54). The increase in thyroid weight
of ThrbPV/PVKrasG12D mice was 80-, 60-, and 2.6-fold greater than
in WT, KrasG12D, and ThrbPV/PV mice, respectively (bar 4 vs 1, bar 4
vs 2, bar 4 vs 3; Figure 1C).
Increased Thyroid Growth in ThrbPV/PVKrasG12D Mice Is Not
Mediated by Elevated TSH Levels
TSH is the major stimulator of thyrocyte proliferation, and its levels
are regulated by the thyroid hormones (T4 and T3) through a negative
feedback loop [17]. To evaluate whether TSH could contribute to the
markedly increased thyroid growth in ThrbPV/PVKrasG12D mice, we
compared serumTSH, serum total T4, and total T3 betweenThrbPV/PV
and ThrbPV/PVKrasG12D mice (Figure 2). There were no significant
differences between ThrbPV/PV and ThrbPV/PVKrasG12D mice in serum
levels of TSH (WT: 38.3 ± 7.4 ng/ml,n = 18;KrasG12D: 14.8 ± 4.2 ng/ml,
n = 10; ThrbPV/PV: 28420 ± 6969 ng/ml, N = 9; ThrbPV/PVKrasG12D:
39990 ± 5331 ng/ml, n = 11; Figure 2A), total T4 (WT: 2.6 ± 0.2 μg/ml,
n = 10;KrasG12D: 4.0 ± 0.5 μg/ml,n = 9;ThrbPV/PV: 27.7 ± 1.3 μg/ml,n =
14;ThrbPV/PVKrasG12D: 19.6 ± 2.7 μg/ml, n = 9; Figure 2B), and total T3
(WT: 1.0 ± 0.1 ng/ml,N = 6;KrasG12D: 1.0 ± 0.2 ng/ml,n = 9;ThrbPV/PV:
7.2 ± 0.7 ng/ml, n = 9; ThrbPV/PVKrasG12D: 4.9 ± 0.9 ng/ml, n = 10;
Figure 2C). These data indicated that KrasG12D activation in thyroids
did not further affect the hypothalamus-pituitary-thyroid axis in
ThrbPV/PVKrasG12D mice. Thus, the increased thyroid weight in
ThrbPV/PVKrasG12Dmice was not due to an elevatedTSH level (Figure 2A).
Increased Proliferation of Thyroid Tumor Cells in
ThrbPV/PVKrasG12D Mice
To determine whether the increased thyroid growth was due to
increased proliferation of tumor cells in ThrbPV/PVKrasG12D mice, we
examined BrdU incorporation in the thyroids of mice with four
genotypes (Figure 3A). As a positive control, we also examined BrdU
incorporation in the intestines. Intensively stained cells were seen in
the intestines (Figure 3, A-e and A-f). In contrast, no nuclei with
BrdU-positive cells were observed in the thyroid sections of WT mice
(Figure 3A-a), and only a few were detected in the thyroid sections of
KrasG12D mice (Figure 3A-b). However, nuclei with BrdU
incorporation were clearly detected in thyroid sections of ThrbPV/PV
mice (Figure 3A-c) and ThrbPV/PVKrasG12D mice (Figure 3A-d), with
significantly more in the ThrbPV/PVKrasG12D than the ThrbPV/PV
Figure 1. Poorsurvival of ThrbPV/PVKrasG12Dmice. (A-I) Protein levelsofERKandAKT in the thyroidsofWT,KrasG12D, ThrbPV/PV, and ThrbPV/PVKrasG12D
mice.Western blot analyses for p-ERK (a), total ERK (b), phosphorylatedAKT (c), total AKT (d), andGAPDH (e), as loading control,were carried out as
described in the Materials and Methods section. Representative results from two mice are shown and the genotypes are marked. (A-II) The band
intensities were quantified by image analysis and p-ERK/total ERK ratios were determined using GAPDH as loading control. (A-III) The band
intensities were quantified by image analysis and p-AKT/total AKT ratios were determined using GAPDH as loading control. (B) The Kaplan-Meier
survival curves forWT,KrasG12D, ThrbPV/PV, and ThrbPV/PVKrasG12Dmiceup to 10.5monthsof age. TheKaplan-Meier cumulative survival analysiswas
performed using GraphPad Prism version 5.0 for Mac OS X. Survival rates of ThrbPV/PVKrasG12D (n = 42) and mice with other genotypes were
significantly different (P b .01). (C) Thyroid glands of themicewith four genotypes (n=9-22)were dissected and compared in the same age groups.
Thedifference in the thyroidweightbetweenThrbPV/PVKrasG12Dmiceand themicewithothergenotypeswassignificant at 2 to10.4months (Pb .01),
as determined by ANOVA.
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of cells undergoing active cell cycling within a 2-hour BrdU-labeling
period, we calculated the average ratios of BrdU-positive cells to total
cells from 10 to 12 bright fields at high magnification (×400) of each
section. The quantitative data are shown in Figure 3B. In WT mice,
no BrdU-positive stained cells were observed (bar 1, Figure 3B). In
KrasG12D mice, less than 1% of cells were BrdU-positive (bar 2,
Figure 3B). However, 3.8% of cells from ThrbPV/PV mice were actively
proliferating (bar 3, Figure 3B). In ThrbPV/PVKrasG12D mice, the ratio
increased to 9.3% (bar 4, Figure 3B), indicating a 2.4-fold increase in
the proliferation of thyroid tumor cells of ThrbPV/PVKrasG12D mice.
These findings indicated that enhanced proliferation contributed to the
marked thyroid enlargement of ThrbPV/PVKrasG12D mice.
ThrbPV/PVKrasG12D Mice Develop Anaplastic Foci with
High Frequency
We performed histopathologic analysis to determine whether
ThrbPV/PVKrasG12D mice developed undifferentiated thyroid cancer(Figure 4A). Thyroids of KrasG12D mice exhibited no apparent
abnormalities. As we previously observed, thyroid of the ThrbPV/PV
mouse displayed extensive hyperplasia at an early stage (data not
shown). In the thyroid of ThrbPV/PVKrasG12D mice, aggressive
phenotypes were apparent at the age of 1 to 2 months. Hyperplasia
(Figure 4A-a), advanced capsular invasion (Figure 4A-b), and vascular
invasion (Figure 4A-b) were frequently observed at a younger age of 2 to
5 months. Moreover, lung metastases (Figure 4A-e) were frequently
observed inThrbPV/PVKrasG12Dmice at the same age. Themetastases in
the heart were also observed inThrbPV/PVKrasG12Dmice (Figure 4A-f ).
Importantly, we identified many anaplastic foci (Figure 4A-c,
indicated by arrows) at the young age of 2 to 5 months under low
magnification.Under highmagnification (×400; Figure 4A-d, indicated
by arrow), it was clear that the anaplastic foci completely lost the normal
morphology of thyroid follicular cells. These observations indicated that
ThrbPV/PVKrasG12D mice developed undifferentiated thyroid cancer.
The detailed pathohistologic analyses are summarized in Figure 4B.
From 2 to 5 months of age, all ThrbPV/PV mice and ThrbPV/PVKrasG12D
Figure 2. No significant differences in thyroid function tests between ThrbPV/PV and ThrbPV/PVKrasG12D mice. Serum total TSH (A), total T4
(TT4, B), and total T3 (TT3, C) of WT, KrasG12D, ThrbPV/PV, and ThrbPV/PVKrasG12D mice were determined as described in the Materials and
Methods section. The P values are marked (n = 5-14).
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in the thyroid was found in 94% of the ThrbPV/PVKrasG12D mice but
only 25% of theThrbPV/PVmice at the same age (Figure 4B-a). Vascular
invasion developed in the thyroids of 4% of ThrbPV/PV mice and 75%Figure 3. Proliferation of thyroid tumor cells is increased in ThrbP
(b), ThrbPV/PV (c), and ThrbPV/PVKrasG12D (d) mice was revealed by Br
section. A representative imageofBrdU-positive thyrocytes (indicated b
Small intestine tissues ofWT (e) and KrasG12D (f) micewere used as pos
positive cells in thyroid sections of WT, KrasG12D, ThrbPV/PV, and ThrbPV
cells was determined from 10 to 12 bright fields, as shown in A.of ThrbPV/PVKrasG12D mice (Figure 4B-b). It was noted that thyroid
anaplasia, which was not observed before 5 months of age in ThrbPV/PV
mice, occurred at the young age of 2 to 5months inThrbPV/PVKrasG12D
mice. At age of 2 to 5 months, 63% of ThrbPV/PVKrasG12D miceV/PVKrasG12D mice. (A) Thyrocyte proliferation in WT (a), KrasG12D
dU incorporation assay as described in the Materials and Methods
y arrows) in different groupsofmice is shown at×400magnification.
itive controls of highly proliferative tissues. (B) Quantification of BrdU-
/PVKrasG12D mice. The percentage of BrdU-positive cells versus total
Figure 4. Histopathologic features of thyroid carcinoma of ThrbPV/PVKrasG12D mice. (A) H&E staining of thyroids, lung, or heart from the
ThrbPV/PVKrasG12D mice. Panels show (a) hyperplasia, (b, arrow) capsular invasion and vascular invasion, (c and d, arrows), anaplastic foci,
(e, arrow), microscopic lung metastases, and (f, arrow) heart metastases in ThrbPV/PVKrasG12D mice at 2 to 5 months of age. (B) Quantitative
analysis of occurrence frequency (%) of (a) capsular invasion, (b) vascular invasion, (c) anaplastic foci, and (d) lungmetastasis ofWT, KrasG12D,
ThrbPV/PV, and ThrbPV/PVKrasG12D mice. Sections of thyroids and lungs were stained with H&E and analyzed for pathologic progression. The
data are expressed as the percentage of occurrence frequency of the mice examined. The designation (#) indicates zero occurrence
frequency (%).
762 MYC in undifferentiated thyroid cancer Zhu et al. Neoplasia Vol. 16, No. 9, 2014developed anaplasia, whereas no ThrbPV/PV mice did (Figure 4B-c).
Metastasis in the lung occurred in 31% of ThrbPV/PVKrasG12D mice at
age of 2 to 5 months, but no metastasis was detected inThrbPV/PV mice
at the same age (Figure 4B-d). Interestingly, metastasis in the heart was
also observed in ThrbPV/PVKrasG12D mice (6%; Figure 4A-f ).
These results show that while ThrbPV/PV mice developed differentiated
thyroid cancer,ThrbPV/PVKrasG12D mice developed aggressive anaplastic
thyroid carcinomas.
Decreased Expression of the Transcription Factor PAX8 andTTF1
Genes in Thyroid Anaplastic Foci in ThrbPV/PVKrasG12D mice
Thyroid-specific transcription factors, PAX8 and TTF1, are
essential for thyroid organogenesis and differentiation. It is known
that decreased PAX8 nuclear abundance was detected in anaplastic
carcinomas [18] and that TTF1 is often lost in anaplastic thyroid
cancer [19]. We therefore analyzed the expression of the PAX8 and
TTF1 protein levels by Western blot assays. In all thyroid tumors of
ThrbPV/PV mice, we detected abundant PAX8 and TTF1 proteins
(panels a and b, lanes 5 and 6; Figure 5, A and B), which were
significantly higher than those in WT or KrasG12D mice (panels a and
b, lanes 1-4; Figure 5, A and B). However, we detected two major
expression patterns of PAX8 and TTF1 proteins in thyroid tumors of
ThrbPV/PVKrasG12D mice (Figure 5, A and B). One prominent
pattern was the reduced abundance of PAX8 and TTF1 proteins
(lanes 7-9, Figure 5A) that was clearly lower than that in WT mice
(lanes 1 and 2), KrasG12D mice (lanes 3 and 4), and ThrbPV/PV mice(lanes 5 and 6). However, in some thyroid tumors, the abundance of
PAX8 and TTF1 proteins was at a similar level as that in ThrbPV/PV
mice (Figure 5B, lanes 7 and 8 vs lanes 5 and 6).
The findings that these two thyroid differentiation markers
displayed two different patterns prompted us to use immunohisto-
chemical analysis to probe further their distribution and abundance in
thyroid tumor cells. The nuclear staining of PAX8 in the thyroid of
WT mice was clearly evident (Figure 5C-Ia). Intensive staining
of PAX8 was also detected in the tumor cells of ThrbPV/PV mice
(Figure 5C-Ib), indicating that thyroid epithelial cells were well
differentiated. In the thyroid tumors of ThrbPV/PVKrasG12D mice,
two patterns were apparent. For well-differentiated thyroid tumors
without any anaplastic foci, the stained intensity of PAX8 proteins
was similar to tumor cells observed in ThrbPV/PV mice. For the
undifferentiated tumors with anaplastic foci, there was only
background staining for the PAX8 proteins, indicating the loss of
PAX8 expression as outlined by dots (Figure 5C-Ic). Similarly,
intensive TTF1 nuclear staining was detected in the thyroid of
WT mice (Figure 5C-IIa) and in the tumor cells of ThrbPV/PV mice
(Figure 5C-IIb). In contrast, it was clear that staining of the nuclear
TTF1 in the anaplastic foci was markedly reduced (Figure 5C-IIc).
These results suggest that consistent with findings in human
anaplastic thyroid cancer [19], the loss of PAX8 and TTF1 expression
was associated with loss of differentiation of thyroid follicular cells and
that the expression of PAX8 or TTF1 was related to the differentiation
status of thyroid tumors.
Figure 5. Decreased expression of transcription factor PAX8within anaplastic foci in thyroid carcinomas of ThrbPV/PVKrasG12Dmice. (A and B)
Protein level of PAX8 (a) and TTF1 (b) and loading control GAPDH (c) in WT, KrasG12D, ThrbPV/PV, and ThrbPV/PVKrasG12D thyroids as marked.
Total protein extractswere prepared from thyroids ofWTand KrasG12Dmice and thyroid tumors of ThrbPV/PV and ThrbPV/PVKrasG12Dmice aged
2 to 5 months. (C) Immunohistochemical analysis of protein abundance of the PAX8 (I) and TTF1 (II) in thyroids. Sections of thyroids derived
from WT (a), ThrbPV/PV (b), and ThrbPV/PVKrasG12D (c) mice were treated with anti-PAX8 or TTF1 antibodies as described in the Materials and
Methods section. The anaplastic foci in the thyroid tumors are outlined by dots. (D) The mRNA level of the Pax8 genewasmeasured by real-
time RT-PCR. Reactionswere performed in 50 ng of total RNA from fivemouse thyroid samples fromeach group.Gapdh genewas used as a
reference. A lower level of Pax8mRNA was detected in ThrbPV/PVKrasG12D mice than in WT mice.
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tumors with anaplastic foci. As shown in Figure 5D, Pax8 mRNA
expression was lower (35% reduction, n = 12) in ThrbPV/PVKrasG12D
mice (bar 4, Figure 5D) than in WT mice (bar 1). The decreased
Pax8mRNA expression suggested that the PAX8 was likely, at least in
part, the effector/regulator of undifferentiation in thyroid carcinoma.
MYC and PAX8 Protein Levels Are Inversely Correlated in
Thyroid Tumors of ThrbPV/PVKrasG12D Mice
To dissect the molecular events responsible for promoting
dedifferentiation in the thyroid tumors of ThrbPV/PVKrasG12D mice,
we screened for altered expression in regulators known to be involved
in the dedifferentiation process. We considered MYC because
abnormal MYC expression is associated with dedifferentiation
[20,21] and MYC is commonly elevated in anaplastic thyroid cancer
[22,23]. Indeed, we found a consistent inverse correlation of MYC
with PAX8 and TTF1 at the protein level in the thyroid tumors of
ThrbPV/PVKrasG12D mice. As shown in Figure 6A, the MYC protein
level was highly elevated in thyroid tumors of ThrbPV/PVKrasG12D
mice (panel a, lanes 7-10, representative examples from 10
undifferentiated thyroid tumors) in which PAX8 and TTF1 protein
levels were low (lanes 7-10 in panels b and c; significant correlation
with Chi-square test: P b .05). For all thyroid tumors of ThrbPV/PV
mice examined (representative examples, lanes 5 and 6, panel a,
Figure 6A) and six thyroid tumors of ThrbPV/PVKrasG12D mice
without undifferentiated thyroid cancer, MYC protein levels were
relatively low (lanes 11 and 12, panel a, Figure 6A), while TTF1 and
PAX8 protein levels were higher (lanes 11 and 12, panels b and c;
significant correlation with Chi-square test: P b .05). Very low MYCprotein abundance was observed in WT mice (lanes 1 and 2,
Figure 6A-a) and KrasG12D mice (lanes 3 and 4, Figure 6A-a), while
TTF1 and PAX8 protein levels were high (lanes 1-4, Figure 6A, panels b
and c). The band intensities in Figure 6Awere quantified, and Figure 6B
shows the quantitative data for MYC (panel a), TTF1 (panel b), and
PAX8 (panel c) with different phenotypes. Consistent with the reports
that MYC is commonly elevated in anaplastic thyroid cancer [22,23],
these results strongly suggest that MYC is associated with the
dedifferentiation process of tumor cells of ThrbPV/PVKrasG12D mice.
We also examined the protein abundance of BIM, a proapoptotic
protein, whose expression could be repressed by MYC [24,25].
Figure 6A-d shows that low BIM protein levels (lanes 7-10, panel d )
were accompanied by high MYC protein levels in dedifferentiated
tumor cells of ThrbPV/PVKrasG12D mice and that high levels of BIM
was associated with low MYC in differentiated tumors (lanes 11 and
12, panel d). The quantitative data of BIM are shown in Figure 6B-d.
These findings indicate that lower BIM protein levels decreased
apoptosis to increase tumor growth of ThrbPV/PVKrasG12D mice.
KRASG12D Collaborates with TRβPV to Increase
the MYC Expression
To examine whether co-expression of KRASG12D and TRβPV
could upregulate MYC expression, we infected rat thyroid pccl3 cells
with adenoviral vectors to express KRASG12D, TRβ, TRβPV, or both
KRASG12D and TRβPV. As shown in Figure 7A, neither KRASG12D
(bars 3 and 4), TRβ (bars 5 and 6), nor TRβPV (bars 7 and 8) alone
significantly increaseMycmRNA expression. In fact, in the presence of
T3, TRβ significantly decreased theMyc mRNA expression. However,
co-expression of KRASG12D and TRβPV led to a significant increase in
Figure 6. Inverse correlation of elevatedMYC level with PAX8 and TTF1 proteins. (A) Total protein extracts were prepared from thyroids of
WT (n= 10) and KrasG12D (n= 10) mice and thyroid tumors of ThrbPV/PV (n= 12) and ThrbPV/PVKrasG12D (n= 16) mice aged 2 to 5 months.
Western blot analysis was carried out for MYC (a), TTF1 (b), PAX8 (c), BIM (d), and GAPDH (e) as described in the Materials and Methods
section, and the representative examples are shown. (B) The band intensities of MYC (a), TTF1 (b), PAX8 (c), and BIM (d) were quantified
by image analysis and relative band intensities were determined using GAPDH as loading control. Bar 1 is fromWT mice; bar 2, KrasG12D
mice; bar 3, ThrbPV/PV mice; bar 4, anaplastic thyroid tumors of ThrbPV/PVKrasG12D mice (lanes 7-10 of Figure 6A); and bar 5, tumors
without anaplasia of ThrbPV/PVKrasG12D mice (lanes 11-12 of Figure 6A).
764 MYC in undifferentiated thyroid cancer Zhu et al. Neoplasia Vol. 16, No. 9, 2014Myc mRNA expression (Figure 7A, bars 9 and 10). Similarly, Western
blot analysis indicated that neither KRASG12D, TRβ, nor TRβPV alone
increased the abundance ofMYCproteins (lanes 3 and 4, 5 and 6, and 7
and 8, respectively). In the presence of T3, TRβ significantly decreased
abundance of MYC. However, co-expression of KRASG12D and
TRβPV significantly increased the abundance of MYC proteins
(Figure 7B, lanes 9 and 10; Figure 7C, bars 9 and 10). The results
indicated the T3-bound TRβ acted as a negative regulator of MYC
expression and that TRβPVwas no longer able to inhibit the expression
ofMYC asTRβ did in the presence of T3. Instead, TRβPV collaborated
with KRASG12D to upregulate MYC in the pccl3 cells.
MYC Collaborates with TRβPV to Suppress the Expression of
the Pax8 Gene, Increase Proliferation, and Inhibit Apoptosis
That the decreased expression of Pax8 mRNA was associated with
anaplastic foci prompted us to understand how the expression of Pax8
was regulated in the thyroid tumors ofThrbPV/PVKrasG12Dmice. Nitsch
et al. identified an element in a distant upstream location of the Pax8
gene known as lnon-coding genomic sequence (CNS) 87 (CNS87),which is responsible for the Pax8 expression in thyroid epithelial cells
[16]. We examined the CSN87 sequence and identified one potential
thyroid hormone receptor response element (TRE) with two half-
binding sites separated by five bases (Supplemental Figure S1-A). We
designated this element as CNS-TRE. Using gel mobility shift, we
found that TRβ bound to CNS-TRE as homodimers and heterodimers
with the retinoid acid receptor (RXR) in a concentration-dependent
manner (Supplemental Figure S1-B, lanes 4-6). The binding specificity
was confirmed by antibody-induced supershift and by competition with
unlabeled TRE (lanes 7 and 9, respectively). Similarly, TRβPV also
bound to CNS-TRE as homodimers and as heterodimers with RXR
(lanes 11-13). The binding specificity was also confirmed by antibody-
induced supershift and by competition with unlabeled TRE (Supple-
mental Figure S1-B, lanes 14 and 16, respectively). We next mutated
one base in each half-binding site to see whether binding of CNS-TRE
toTRβwas specific (Supplemental Figure S1-A). As controls, both TRβ
and TRβPV bound to CNS-TRE as homodimers and as heterodimers
with RXR (Supplemental Figure S1-C, lanes 4 and 8). After wemutated
one base in the half-binding site, neither TRβ nor TRβPV could any
Figure 7. KRASG12D together with TRβPV increases the abundance of MYC in rat thyroid pccl3 cells. (A) The mRNA level of theMyc gene
was measured by real-time RT-PCR in the pccl3 cells infected with control adenoviral vector or adenoviral vectors expressing KRASG12D,
TRβWT, TRβPV, or both KRASG12D and TRβPV. Reactions were performed in 200 ng of total RNA from adenovirus-infected pccl3 cells.
Gapdh gene was used as a reference. (B) Protein level of MYC in the pccl3 cells infected with control adenoviral vector or adenoviral
vectors expressing KRASG12D, TRβWT, TRβPV, or both KRASG12D and TRβPV. Total protein extracts were prepared from the pccl3 cells 18
hours after adenovirus infection. (C) The band intensities were quantified by image analysis and relative band intensities were determined
using GAPDH as loading control.
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analyses confirmed that binding of TRβ or TRβPV to CNS-TRE was
specific. Using the luciferase reporter in established rat thyroid pccl3
cells stably expressing TRβ, we examined whether TRE-containing
CNS87 could mediate the T3-dependent TRβ transcriptional activity.
In the presence of TRβ, luciferase activity was increased by about two-
fold (Supplemental Figure S1-D). Addition of T3 further increased
the luciferase activity (bar 4 vs bar 3). When mutated CNS-TRE was
used, no reporter activity was detected (bars 5 and 6; Supplemental
Figure S1-D). The results indicated that CNS87 in the Pax8 gene was
regulated by TRβ.
Comparison of the CNS87 reporter activities shows that TRβPV
had lower luciferase activity than TRβ (Figure 8A, bar 4 vs bar 2). The
lower luciferase activity mediated by TRβPV suggested that TRβPV
could act to repress the Pax8 expression within the anaplastic foci.
Furthermore, other cellular regulator could collaborate with TRβPV
to further suppress the expression of the Pax8 gene. The strong
association between the elevated MYC level and reduced PAX8
prompted us to examine whether the high MYC could collaborate
with TRβPV to repress the Pax8 expression in the thyroid tumors of
ThrbPV/PVKrasG12D mice. Accordingly, we examined whether MYC
affected the binding of TRβ or TRβPV to CNS-TRE. Figure 8B-ashows that TRβ and TRβPV bound to CNS-TRE as homodimers
and heterodimers with RXR in a dose-dependent manner (lanes 3-6
and 8-11, respectively). However, in the presence of MYC, the
binding intensity was reduced (Figure 8B-a, lanes 12-15 and 16-19,
respectively). Quantitative analysis indicated that binding intensities
for TRβ and TRβPV were reduced in the presence of MYC
(Figure 8B-b), suggesting that MYC could weaken the binding
of TRβ and TRβPV to CNS-TRE through direct or indirect
interference. To ascertain the functional consequence of decreased
binding of TRβPV binding to CNS-TRE by MYC, we carried out
luciferase activities in thyroid pccl3 cells stably expressing TRβPV
alone or together with MYC. Because TRβPV does not bind T3,
luciferase activities in the presence of MYC were reduced in a T3-
independent manner (Figure 8C, bars 3 and 4 vs bars 1 and 2). Taken
together, these data suggested that MYC could collaborate with
TRβPV to suppress the expression of the Pax8 gene and induce the
dedifferentiation of thyroid tumor cells.
It is known that in mammalian cells MYC not only regulates
terminal differentiation but also stimulates cell proliferation
and induces apoptosis [26]. Since the thyroid tumor cells of
ThrbPV/PVKrasG12D mice proliferated faster than the thyroid cells of
WT mice, KrasG12D mice, and ThrbPV/PV mice (see Figures 1C and 3),
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ofThrbPV/PVKrasG12Dmice (see Figure 6) led to increased expression of
the key regulators of cell proliferation. Consistent with upregulated
MYC shown in Figure 6, cyclin D1 was most abundantly upregulated
in the thyroid tumor cells of ThrbPV/PVKrasG12D mice (lanes 7-8;
Figure 9A-a) as compared with WT mice (lanes 1-2), KrasG12D mice
(lanes 3-4), and ThrbPV/PV mice (lanes 5-6, Figure 9A-a). Moreover, we
also found that B-cell lymphoma 2 (BCL-2), a critical anti-apoptotic
regulator, was expressed at the highest level in the thyroid tumor cells of
ThrbPV/PVKrasG12D mice (lanes 7-8, Figure 9A-b). Panel c shows the
loading controls of GAPDH. Our findings of downregulated BIM and
higher BCL-2 in the thyroids of ThrbPV/PVKrasG12D mice indicate that
the synergistic signaling of KRASG12D and TRβPV mutants led to
increased proliferation and decreased apoptosis through up-regulation
of MYC.
Previously, we have shown that β-catenin was activated in the
thyroid tumors of ThrbPV/PV mice [10]. To ascertain whether β-
catenin signaling was affected in the thyroid tumor progression of
ThrbPV/PVKrasG12D mice, we evaluated the protein abundance of
nuclear β-catenin in mice with different genotypes by immunohis-
tochemistry (Figure 9B-I). The thyroid of WT mice shows the usual
flattened nuclei in the wall of the follicles with no detectable signal for
β-catenin (panel b). The thyroid of the KrasG12D mice showed a more
cellular follicle with many nuclei in a double layer of adjacent follicle
nuclei and little detectable β-catenin. Thyroid tumors of ThrbPV/PV
mice showed extensive adenomatous hyperplasia with some degree
of cellular heterogeneity as to size and shape and similarly showed
heterogeneity in the intensity of the nuclear β-catenin signal (panel f,
Figure 9B-I). However, the thyroid tumors of ThrbPV/PVKrasG12D
mice showed uniform high cellularity and the nuclei showed
homogeneously high levels of nuclear β-catenin (panel h, Figure 9B-
I). Panels a, c, e, and g are the corresponding negative controls in which
no primary antibodies were used.We further counted the cells positivelyFigure 8.MYC together with TRβPV suppresses the activities of Pax8
mediated by Pax8 upstream enhancer reporter in the absence or prese
2) or TRβPV (bars 3 & 4). (B-a) Binding of TRβ or TRβPV to the CNS-
Electrophoretic mobility gel shift assay was carried as described i
Quantification of the band intensities of the TR/RXR heterodimers is
reduced in the presence of overexpressed MYC. Luciferase gene rep
reporter in rat thyroid pccl3 cells stably expressing TRβPV alone or wstained with anti–β-catenin antibodies in the nuclei of thyroids in mice
with four genotypes (Figure 9B-II).We found that 3.4-fold (bar 3 vs bar
1) and 5.3-fold (bar 4 vs bar 1) more cells were stained with anti–β-
catenin antibodies in the thyroid of ThrbPV/PV and ThrbPV/PVKrasG12D
mice, respectively, than in the WTmice. These results represented that
an additional 1.6-fold more β-catenin was present in the nuclei of
thyroids of ThrbPV/PVKrasG12D mice than in ThrbPV/PV mice. These
findings indicate the contributions of increased activation of β-catenin
in promoting thyroid carcinogenesis of ThrbPV/PVKrasG12D mice.
Discussion
Association studies have indicated that mutations of PIK3CA, AKT1,
PTEN, CTNNB1, RAS, and BRAF are common in anaplastic thyroid
cancer [1]. These prevalent mutations suggest that the activation of
PI3K-AKT, MAPK, and β-catenin signaling are critical in the
development of undifferentiated thyroid cancer. Of these three major
signaling pathways, it is still unknown which is essential to bring
about dedifferentiated thyroid cancer. Studies from mouse models
indicated that activated mutation of the Kras gene alone did
not induce thyroid cancer. Simultaneous activation of the PI3K
(through deletion of the Pten gene) and KRAS signaling led to only
differentiated follicular thyroid carcinoma [2]. These findings suggest
that additional genetic events are needed for the dedifferentiation to
occur. In the present studies, we introduced KrasG12D mutation into
ThrbPV/PV mice in which PI3K-AKT and β-catenin signaling are
activated, leading to undifferentiated thyroid cancer [8,10,27,28].
Consistent with findings by Miller et al. [2], we found that mice
harboring the activated KrasG12D mutation alone showed no signs of
thyroid cancer. Remarkably, ThrbPV/PV mice harboring the activated
KrasG12D mutation developed undifferentiated thyroid cancer. These
findings suggest that cross talks of the activated KRAS pathway with
the activated PI3K-AKT and β-catenin signaling mediated by TRβPV
induced dedifferentiated thyroid cancer. THRB gene mutationsenhancer element. (A) Comparison of luciferase reporter activities
nce of T3 in rat thyroid pccl3 cells stably expressing TRβ (bars 1 and
TRE in the absence (lanes 2-11) or presence (lanes12-19) of MYC.
n the Material and Methods section. Lanes are as marked. (B-b)
shown in A-a. (C) T3/TRβ-induced reporter activity was markedly
orter assays were performed using the CNS87 element luciferase
ith both TRβPV and MYC.
Figure 9. Increased protein abundance of key cellular regulators to promote thyroid tumor progression of ThrbPV/PVKrasG12D mice.
(A) Western blot analysis of cyclin D1 and BCL-2 with GAPDH as loading control. Representative results from two mice are shown
and the genotypes are marked. (B) Increased nuclear localization of β-catenin in thyroid tumors of ThrbPV/PVKrasG12D mice. (B-I)
Immunohistochemical analysis of β-catenin in thyroid of four genotypes, as marked, was carried out as described in the Materials and
Methods section. Highly elevated β-catenin was apparent in the tumor nuclei of ThrbPV/PVKrasG12D mice. (B-II) Quantitative analysis of thyroid
cells positively stained with anti–β-catenin bodies. The β-catenin–positive cells were counted by using NIH ImageJ software (Wayne Rasband,
National Institutes of Health, Bethesda, MD). All data are expressed as mean ± SEM (n = 3). Significant differences between groups
were calculated using ANOVA test with the use of GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA). P b .05 is considered
statistically significant.
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[29–34]. Thousands of rare mutations have been identified in the
human genome. Our observations that KRASG12D together
with TRβPV promoted the development of undifferentiation of
thyroid cancer in mice make it possible that the cross signaling of
common mutation and rare genetic event affect the progression of
cancer. Their interaction may explain the heterogeneity of human
cancer in the population.
To understand how the activated KRAS signaling collaborated with
the TRβPV oncogenic events, thus leading to dedifferentiated thyroid
cancer, we first considered the possible contribution of the elevated
TSH to the dedifferentiated phenotype of ThrbPV/PVKrasG12D mice.
However, as shown in Figure 2A, there were no significant differences in
the serumTSH levels betweenThrbPV/PVmice andThrbPV/PVKrasG12D
mice. Thus, TSH is unlikely to play a major role in the aggressive
undifferentiated phenotype detected in ThrbPV/PVKrasG12D mice.
Given the absence of differences in serum thyroid hormone levelsbetween ThrbPV/PV mice and ThrbPV/PVKrasG12D mice, we also ruled
out the possibility that thyroid hormone levels contributed to the
aggressive undifferentiated thyroid cancer in ThrbPV/PVKrasG12D mice.
This notion is consistent with observations that the KrasG12D mutation
alone in the thyroid ofKrasG12Dmice had no effect on the pituitary-thyroid
axis, as shown in our present studies (see Figure 2) as well as in the studies
reported by Miller et al. [2]. In addition, mice with the activated RAS
mutation alone failed to induce thyroid cancers even in the presence of
an elevated TSH level induced by propylthiouracil (PTU) for 20 weeks
[3]. These findings demonstrated that not TSH but other oncogenic
events were responsible for the aggressive undifferentiated thyroid
carcinogenesis of ThrbPV/PVKrasG12D mice.
MYC is one key oncogene that could play a critical role in the
development of undifferentiated thyroid cancer of ThrbPV/PVKrasG12D
mice. We found that it was highly upregulated and, more importantly,
tightly inversely correlated with the loss of the differentiation markers
PAX8 and TTF1 (Figure 6A) in the anaplastic foci. Furthermore, using
768 MYC in undifferentiated thyroid cancer Zhu et al. Neoplasia Vol. 16, No. 9, 2014rat thyroid pccl3 cells, we found that co-expression of KRASG12D and
TRβPV upregulated the levels of MYC at both the mRNA and protein
levels (Figure 7). Although it is not yet clear howMYCwas upregulated
in the anaplastic tumors of ThrbPV/PVKrasG12D mice, up-regulation of
MYC by KRASG12D/TRβPV in the rat thyroid pccl3 cell line and the
tight inverse association with PAX8 and TTF1 lead us to argue for the
critical involvement of MYC in the induction of undifferentiated
thyroid tumors inThrbPV/PVKrasG12Dmice. This postulate is consistent
with other studies that support MYC’s key role in the differentiation
process. MYC has been recognized as one of the most highly amplified
oncogenes in human cancers [35]. Cell differentiation leads to down-
regulation of the MYC expression, and overexpression of MYC results
in the dedifferentiation phenotype [36]. Overexpressed MYC is also
known to inhibit Ras-mediated differentiation by blocking c-Jun up-
regulation [37] (Supplemental Figure S2). MYC also plays a key role in
reprogramming human somatic cells to pluripotent stem cells [38,39].
In the above studies, however, the mechanisms by whichMYC induces
dedifferentiation were not clearly elucidated. In the present studies, we
uncovered one mechanism by which MYC could act to participate in
the induction of dedifferentiated thyroid cancer of ThrbPV/PVKrasG12D
mice through the repression of one of the differentiation transcription
factors. Molecular analyses showed that TRβPV, which does not bind
T3, repressed the Pax8 gene expression. This repression was further
augmented by MYC, leading to added repression in the Pax8
transcription. At present, we could not rule out the possibility that
MYC could repress the expression of the Pax8 gene through other
mechanisms independent of PV. However, our data could explain the in
vivo findings that the Pax8mRNA level was less than that in WT mice,
KrasG12D mice, and ThrbPV/PV mice (Figure 5D). While mutations of
the THRβ gene are rare in human thyroid cancer [29–34,40], the
collaboration of MYC with TRβ mutants to suppress the expression of
the Pax8 gene has yet to be uncovered. However, our findings
exemplified howMYC could collaborate with other transcription factors
and oncogenes to suppress the expression of the Pax8 gene and thereby
could participate in the induction of the dedifferentiation process. In line
with our findings, others have shown that MYC expressed in transgenic
mice triggers aggressive mammary tumorigenesis by collaborating with a
KRAS mutation [41].
The up-regulation of MYC in the dedifferentiated thyroid cancer
of ThrbPV/PVKrasG12D mice provides insight into a potential
therapeutic intervention. MYC is known to be essential in the
maintenance of established tumors [42,43]. In vitro knockdown of
MYC in established cancer cell lines reduces cell proliferation and, in
some instances, induces apoptosis [44,45]. In transgenic mouse
models with inducible MYC expression, established tumors regress
upon withdrawal of ectopic expressed MYC. These observations
suggest that MYC plays a role in tumor maintenance, and once
established, these tumors are addicted to MYC for maintaining tumor
phenotypes [46]. Studies using mice harboring an activated KrasG12D
mutation showed that the blockade of MYC functions through
systematic induction of a dominant-negative MYC allele resulted in
the regression of lung carcinomas and pancreatic carcinomas [42].
Investigations have further shown that targeting MYC transcription
functions by disruption of chromatin-dependent signal transduction
could be effective as a therapeutic strategy. Indeed, a potent, selective
small-molecule inhibitor of BET bromodomains, JQ1, was developed
[47]. The efficacy of JQ1 was demonstrated in producing potent
antiproliferative effects and cellular senescence in murine models of
multiple myeloma [48,49]. Therefore, inhibiting MYC functionsby small inhibitors could be a novel potential therapeutic strategy
in the treatment of undifferentiated thyroid carcinoma. Thus, the
ThrbPV/PVKrasG12D mouse offers an opportunity not only to further
elucidate the role of the KRAS in the initiation of undifferentiated
thyroid cancer but also to further test novel therapeutic targets as an
intervention for anaplastic thyroid cancer.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.08.003.References
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